- Details
- Neal Shore interviews Alicia Morgans about her poster presentation on the ARAMIS trial. The ARAMIS trial evaluated darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) patients with rising PSA levels and no radiographic evidence of disease. The study found that the combination of ADT and darolutamide extended metastasis-free survival by about two years and increased overall...
|
- Details
- Petros Grivas welcomes Karim Chamie to discuss the exciting developments in urothelial cancer, focusing on the QUILT trial involving BCG unresponsive, high-risk non-muscle invasive bladder cancer patients. Dr. Chamie shares insights into historical treatments, the limitations of current approaches, and the breakthroughs achieved by combining intravesical BCG with the Interleukin-15 super agonist,...
|
- Details
- In this discussion, Susan Slovin and Alicia Morgans discuss the incorporation of PSMA PET imaging and emerging treatments like lutetium-177-PSMA in genitourinary oncology. Referencing ASCO 2022 talks and clinical trials, particularly Dr. Mike Hofman's study comparing lutetium-PSMA and cabazitaxel post-docetaxel, they review three-year data showing no significant difference in overall survival betw...
|
- Details
- Ashley Ross and Alicia Morgans discuss the use of PSMA PET scans in the metastatic CRPC and how the recommendations and guidance have evolved in the NCCN guidelines. Dr. Ross gives an overview of the relevant clinical trials and FDA approvals of key radiotracers and their impact on clinical practice and treatment sequencing, as well as the impact of supply line problems on implementation. Biograph...
|
- Details
- Vivek Narayan joins Alicia Morgans at ASCO 2022 to discuss his work with CAR T-cell therapies and prostate cancer, the first-in-human study. Using a low-dose escalation approach, Dr. Narayan and his team designed the study safety as the primary objective to evaluate the feasibility of manufacturing and delivering the CAR T-cells. He describes how findings showed both on-treatment toxicity and on-t...
|
- Details
- Sarmad Sadeghi and Pedro Barata discuss the results of a randomized Phase II that explored OX40in combination with axitinib in patients with renal cell carcinoma. Patients in the trial had progressive disease after receiving immunotherapy with the usual PD-1/PD-L1 antibodies. The primary endpoint was progression-free survival. Dr. Sadeghi describes the rationale for the trial design, why the trial...
|
- Details
- Petros Grivas speaks with Vadim Koshkin about his groundbreaking research in urothelial cancer imaging. The focus is on Dr. Koshkin's abstract detailing the potential of Fibroblast-Associated Protein (FAP) imaging, a novel technique that targets cells present within the cancer, rather than the cancer cells themselves. The ongoing trial aims to enroll 80 patients with solid malignancies but shows p...
|
- Details
- Join Shahneen Sandhu and Alicia Morgans as they discuss the MAGNITUDE trial and the pre-specified gene-by-gene analysis that Dr Sandhu presented at ASCO 2022. Dr. Sandhu kicks off the conversation with a recap of the MAGNITUDE trial. She then explains how this follow-up study was a pre-specified analysis that looked at the primary endpoints and all the secondary endpoints in patients with at least...
|
- Details
- Alicia Morgans sits down with Charles Ryan to discuss the recent publication of Urologic Oncology: Multidisciplinary Care for Patients, a book she co-edited with Kelly Stratton. Dr. Morgans shares her thoughts on the importance of collaboration across teams in treating patients with GU cancers and provides an overview of key content in the book. Biographies: Alicia Morgans, MD, MPH , Genitourinary...
|
- Details
- Tanya Dorff and Alicia Morgans discuss the importance of multidisciplinary care teams for patients with bone metastatic castration-resistant prostate cancer (mCRPC). The pair talk about the need for clear communication between physicians, radiation oncologists, and nuclear medicine physicians on the team, as well as the importance of the nursing and imaging staff. Dr. Dorff also stresses the impor...
|
